166 related articles for article (PubMed ID: 36029387)
81. Structural basis of divergent cyclin-dependent kinase activation by Spy1/RINGO proteins.
McGrath DA; Fifield BA; Marceau AH; Tripathi S; Porter LA; Rubin SM
EMBO J; 2017 Aug; 36(15):2251-2262. PubMed ID: 28666995
[TBL] [Abstract][Full Text] [Related]
82. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
83. The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer.
Thewes V; Simon R; Hlevnjak M; Schlotter M; Schroeter P; Schmidt K; Wu Y; Anzeneder T; Wang W; Windisch P; Kirchgäßner M; Melling N; Kneisel N; Büttner R; Deuschle U; Sinn HP; Schneeweiss A; Heck S; Kaulfuss S; Hess-Stumpp H; Okun JG; Sauter G; Lykkesfeldt AE; Zapatka M; Radlwimmer B; Lichter P; Tönjes M
Oncogene; 2017 Jul; 36(29):4124-4134. PubMed ID: 28319069
[TBL] [Abstract][Full Text] [Related]
84. Spy1 is frequently overexpressed in malignant gliomas and critically regulates the proliferation of glioma cells.
Zhang L; Shen A; Ke Q; Zhao W; Yan M; Cheng C
J Mol Neurosci; 2012 Jul; 47(3):485-94. PubMed ID: 22447439
[TBL] [Abstract][Full Text] [Related]
85. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
86. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
[TBL] [Abstract][Full Text] [Related]
87. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
88. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
[TBL] [Abstract][Full Text] [Related]
89. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
90. MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding.
Massó-Vallés D; Beaulieu ME; Jauset T; Giuntini F; Zacarías-Fluck MF; Foradada L; Martínez-Martín S; Serrano E; Martín-Fernández G; Casacuberta-Serra S; Castillo Cano V; Kaur J; López-Estévez S; Morcillo MÁ; Alzrigat M; Mahmoud L; Luque-García A; Escorihuela M; Guzman M; Arribas J; Serra V; Larsson LG; Whitfield JR; Soucek L
Cancer Res Commun; 2022 Feb; 2(2):110-130. PubMed ID: 36860495
[TBL] [Abstract][Full Text] [Related]
91. Development of Acridone Derivatives: Targeting
Liang JW; Gao ZC; Yang LL; Zhang W; Chen MZ; Meng FH
Antioxidants (Basel); 2023 Dec; 13(1):. PubMed ID: 38275631
[TBL] [Abstract][Full Text] [Related]
92. Enhanced bacterial cancer therapy delivering therapeutic RNA interference of c-Myc.
Williams JS; Higgins AT; Stott KJ; Thomas C; Farrell L; Bonnet CS; Peneva S; Derrick AV; Hay T; Wang T; Morgan C; Dwyer S; D'Ambrogio J; Hogan C; Smalley MJ; Parry L; Dyson P
Cell Biosci; 2024 Mar; 14(1):38. PubMed ID: 38521952
[TBL] [Abstract][Full Text] [Related]
93. The atypical CDK activator RingoA/Spy1 regulates exit from quiescence in neural stem cells.
Gonzalez L; Domingo-Muelas A; Duart-Abadia P; Nuñez M; Mikolcevic P; Llonch E; Cubillos-Rojas M; Cánovas B; Forrow SMA; Morante-Redolat JM; Fariñas I; Nebreda AR
iScience; 2023 Mar; 26(3):106202. PubMed ID: 36876138
[TBL] [Abstract][Full Text] [Related]
94. The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis.
Fifield BA; Qemo I; Kirou E; Cardiff RD; Porter LA
Breast Cancer Res; 2019 Dec; 21(1):140. PubMed ID: 31829284
[TBL] [Abstract][Full Text] [Related]
95. The requirement for cyclin E in c-Myc overexpressing breast cancers.
Zhou Y; Geng Y; Zhang Y; Zhou Y; Chu C; Sharma S; Fassl A; Butter D; Sicinski P
Cell Cycle; 2020 Oct; 19(20):2589-2599. PubMed ID: 32975478
[TBL] [Abstract][Full Text] [Related]
96. The cyclin-like protein Spy1/RINGO promotes mammary transformation and is elevated in human breast cancer.
Al Sorkhy M; Ferraiuolo RM; Jalili E; Malysa A; Fratiloiu AR; Sloane BF; Porter LA
BMC Cancer; 2012 Jan; 12():45. PubMed ID: 22280365
[TBL] [Abstract][Full Text] [Related]
97. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
98. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
[No Abstract] [Full Text] [Related]
99. Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments.
Ferraiuolo RM; Fifield BA; Hamm C; Porter LA
Breast Cancer Res Treat; 2022 Nov; 196(1):17-30. PubMed ID: 36029387
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
